The mineralocorticoid receptor antagonist eplerenone reduces renal interstitial fibrosis after long-term cyclosporine treatment in rat: antagonizing cyclosporine nephrotoxicity

BMC Nephrology

Peter Bie²  Niels Marcussen¹  Pernille BL Hansen²  Boye L Jensen²  Finn Thomsen Nielsen³ 

[1] Department of Pathology, Odense University Hospital, University of Southern Denmark, Odense, Denmark;Department of Cardiovascular and Renal Research, Institute of Molecular Medicine, University of Southern Denmark, Winsløwparken 21, 3, Odense C, DK-5000, Denmark;Department of Nephrology, State University Hospital, Copenhagen, Denmark

关键词: Renin;    Nephrotoxicity;    Hypertension;    Calcineurin;    Aldosterone;   

Others  :  1082996
DOI  :  10.1186/1471-2369-14-42

 received in 2012-06-08, accepted in 2013-01-31,  发布年份 2013

【 摘 要 】

Background

Chronic cyclosporine-(CsA)-mediated loss of kidney function is a major clinical problem in organ transplantation. We hypothesized that the mineralocorticoid receptor antagonist eplerenone (EPL) prevents chronic CsA-induced renal interstitial volume increase, tubule loss, and functional impairment in a rat model.

Methods

Sprague–Dawley rats received CsA alone (15 mg/kg/d p.o.), CsA and EPL (approximately 100 mg/kg/day p.o.) or vehicle (control) for 12 weeks. At 11 weeks, chronic indwelling arterial and venous catheters were implanted for continuous measurements of arterial blood pressure (BP) and GFR (inulin clearance) in conscious, freely moving animals. Plasma was sampled for analysis and kidney tissue was fixed for quantitative stereological analyses.

Results

Compared to controls, CsA-treatment reduced relative tubular volume (0.73±0.03 vs. 0.85±0.01, p<0.05) and increased relative interstitial volume (0.080±0.004 vs. 0.045±0.003, p<0.05); EPL attenuated these changes (0.82±0.02, p<0.05, and 0.060±0.006, p<0.05, respectively). CsA-treated rats had more sclerotic glomeruli and a higher degree of vascular depositions in arterioles; both were significantly reduced in CsA+EPL-treated animals. CsA increased BP and reduced body weight gain and GFR. In CsA+EPL rats, weight gain, GFR and BP at rest (daytime) were normalized; however, BP during activity (night) remained elevated. Plasma sodium and potassium concentrations, kidney-to-body weight ratios and CsA whole blood concentration were similar in CsA and CsA+EPL rats.

Conclusions

It is concluded that in the chronic cyclosporine rat nephropathy model, EPL reduces renal tissue injury, hypofiltration, hypertension, and growth impairment. MR antagonists should be tested for their renoprotective potential in patients treated with calcineurin inhibitors.

【 授权许可】

   
2013 Nielsen et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Dieperink H, Leyssac PP, Starklint H, Kemp E: Long-term cyclosporine nephrotoxicity in the rat. Effects on renal function and morphology. Nephrol Dial Transplant 1988, 3(3):317-326.
• [2]Nielsen FT, Leyssac PP, Kemp E, Starklint H, Dieperink H: Nephrotoxicity of FK506 in the rat. Studies on glomerular and tubular function, and on the relationship between efficacy and toxicity. Nephrol Dial Transplant 1995, 10(3):334-340.
• [3]McAuley FT, Whiting PH, Thomson AW, Simpson JG: The influence of enalapril or spironolactone on experimental cyclosporine nephrotoxicity. Biochem Pharmacol 1987, 36(5):699-703.
• [4]Iacona A, Rossetti A, Filingeri V, Orsini D, Cesarini A, Cervelli V, Adorno D, Casciani CU: Reduced nephrotoxicity and hepatotoxicity in cyclosporine A therapy by enalapril and spironolactone in rats. Drugs Exp Clin Res 1991, 17(10–11):501-506.
• [5]Feria I, Pichardo I, Juarez P, Ramírez V, González MA, Uribe N, García-Torres R, López-Casillas F, Gamba G, Bobadilla NA: Therapeutic benefit of spironolactone in experimental chronic cyclosporine A nephrotoxicity. Kidney Int 2003, 63(1):43-52.
• [6]Pérez-Rojas J, Blanco JA, Cruz C, Trujillo J, Vaidya VS, Uribe N, Bonventre JV, Gamba G, Bobadilla NA: Mineralocorticoid receptor blockade confers renoprotection in preexisting chronic cyclosporine nephrotoxicity. Am J Physiol Renal Physiol 2007, 292(1):F131-139.
• [7]Macunluoglu B, Arikan H, Atakan A, Tuglular S, Ulfer G, Cakalagaoglu F, Ozener C, Akoglu E: Effects of spironolactone in an experimental model of chronic cyclosporine nephrotoxicity. Transplant Proc 2008, 40(1):273-278.
• [8]Nielsen FT, Jensen BL, Marcussen N, Skøtt O, Bie P: Inhibition of mineralocorticoid receptors with eplerenone alleviates short-term cyclosporine A nephrotoxicity in conscious rat. Nephrol Dial Transplant 2008, 23(9):2777-2783.
• [9]Burgess ED, Lacourcière Y, Ruilope-Urioste LM, Oparil S, Kleiman JH, Krause S, Roniker B, Maurath C: Long-term safety and efficacy of the selective aldosterone blocker eplerenone in patients with essential hypertension. Clin Ther 2003, 25(9):2388-2404.
• [10]Blasi ER, Rocha R, Rudolph AE, Blomme EA, Polly ML, McMahon EG: Aldosterone/salt induces renal inflammation and fibrosis in hypertensive rats. Kidney Int 2003, 63(5):1791-1800.
• [11]Hansen PB, Hristovska A, Wolff H, Vanhoutte P, Jensen BL, Bie P: Uridine adenosine tetraphosphate affects contractility of mouse aorta and decreases blood pressure in conscious rats and mice. Acta Physiol 2010, 200(2):171-179.
• [12]Gabel RA, Ranaei RA, Kivlighn SD: A new method of measuring renal function in conscious rats without the use of radioisotopes. J Pharmacol Toxicol Methods 1996, 36(4):189-197.
• [13]Poulsen K, Jorgensen J: An easy radioimmunological microassay of renin activity, concentration and substrate in human and animal plasma and tissues based on angiotensin I trapping by antibody. J Clin Endocrinol Metab 1974, 39(5):816-825.
• [14]Gundersen HJ, Bendtsen TF, Korbo L, Marcussen N, Møller A, Nielsen K, Nyengaard JR, Pakkenberg B, Sørensen FB, Vesterby A: Some new, simple and efficient stereological methods and their use in pathological research and diagnosis. APMIS 1988, 96(5):379-394.
• [15]Skyum H, Marcussen N, Nielsen SH, Christensen S: Interstitial capillary changes in lithium nephropathy: effects of antihypertensive treatment. APMIS 2004, 112(10):686-697.
• [16]Johansson ME, Andersson IJ, Alexanderson C, Skøtt O, Holmäng A, Bergström G: Hyperinsulinemic rats are normotensive but sensitized to angiotensin II. Am J Physiol Regul Integr Comp Physiol 2008, 294(4):R1240-R1247.
• [17]Hilfenhaus M: Circadian rhythm of the renin-angiotensin-aldosterone system in the rat. Arch Toxicol 1976, 36(3–4):305-316.
• [18]Gumz ML, Stow LR, Lynch IJ, Greenlee MM, Rudin A, Cain BD, Weaver DR, Wingo CS: The circadian clock protein Period 1 regulates expression of the renal epithelial sodium channel in mice. J Clin Invest 2009, 119(8):2423-2434.
• [19]Chander V, Chopra K: Nifedipine attenuates changes in nitric oxide levels, renal oxidative stress, and nephrotoxicity induced by cyclosporine. Ren Fail 2005, 27(4):441-450.
• [20]Chander V, Singh D, Tirkey N, Chander H, Chopra K: Amelioration of cyclosporine nephrotoxicity by irbesartan, a selective AT1 receptor antagonist. Ren Fail 2004, 26(5):467-477.
• [21]Gooch JL, Guler RL, Barnes JL, Toro JJ: Loss of calcineurin Aalpha results in altered trafficking of AQP2 and in nephrogenic diabetes insipidus. J Cell Sci 2006, 119(Pt 12):2468-76.
• [22]Kurtz A, Della Bruna R, Kühn K: Cyclosporine A enhances renin secretion and production in isolated juxtaglomerular cells. Kidney Int 1988, 33(5):947-53.
• [23]Nielsen FT, Ottosen P, Starklint H, Dieperink H: Kidney function and morphology after short-term combination therapy with cyclosporine A, tacrolimus and sirolimus in the rat. Nephrol Dial Transplant 2003, 18(3):491-496.
• [24]Shihab FS, Yi H, Bennett WM, Andoh TF: Effect of nitric oxide modulation on TGF-beta1 and matrix proteins in chronic cyclosporine nephrotoxicity. Kidney Int 2000, 58(3):1174-1185.
• [25]Pérez-Rojas J, Derive S, Blanco JA, Cruz C, Martínez dela Maza L, Gamba G, Bobadilla NA: Renocortical mRNA expression of vasoactive factors during spironolactone protective effect in chronic cyclosporine nephrotoxicity. Am J Physiol Renal Physiol 2005, 289(5):1020-1030.